Scientists Produce New Anti-Malarial Compound

October 08, 1996

Johns Hopkins University scientists have developed new chemical compounds that show promise in fighting malaria, a disease that kills 2 million people a year.

Chemists were able to synthesize the new compounds after learning how another, more expensive and difficult-to-produce malaria drug works at the molecular level. The new compounds use the same mechanism to kill the parasite that causes malaria, but they are much less expensive and easier to produce than drugs presently available.

When tested in laboratory cultures of infected blood, the experimental drugs killed Plasmodium falciparum, the species of mosquito-borne parasite that causes most malaria deaths in people. One of the compounds has been tested on malaria-infected mice, curing the animals. The researchers are working now to develop more potent compounds, leading to more animal testing.

Finding new anti-malarial agents is important because Plasmodium parasites are becoming increasingly resistant to chloroquine and other traditional drugs used to treat malaria patients. The anti- malarial drug artemisinin, extracted from the plant Artemisia annua, has been successful in curing malaria patients in China. But plants contain only small amounts of the substance, making the drug expensive and impractical.

The Hopkins researchers have previously developed synthetic versions, or analogs, of artemisinin; the synthetic drugs have been shown to cure malaria in monkeys. The new compounds, however, would be easier and less expensive to produce than those analogs of artemisinin.

A scientific paper about the compounds was published on Sept. 30 in Tetrahedron Letters, an international science journal published in the United Kingdom. The research is being conducted by a team of scientists led by Gary H. Posner, Scowe Professor of Chemistry in The Johns Hopkins School of Arts and Sciences, and Theresa A. Shapiro, a pharmacologist and associate professor in the School of Medicine.

After figuring out artemisinin's Plasmodium-killing chemistry, the organic chemists were able to make the new compounds. The central component of the mechanism is a ring of atoms, present in atemisinin and the new compounds, that contains two oxygen atoms bound together, a structure called a peroxide.

The researchers found that iron from blood inside the malaria parasite provides a source of electrons that rupture the bond between the two adjacent oxygen atoms in the peroxide structure. The result is an oxygen free radical -- an atom with an unpaired electron. The free radical attracts a hydrogen atom, plucking it away from its bond with a carbon atom and producing an electron- hungry carbon free radical. Carbon radicals damage cells inside the parasite by stealing electrons and breaking molecular bonds, making the drug toxic to the malaria parasite.

"Our understanding of that mechanism has allowed us to design structurally simpler compounds that would follow that chemical mechanism," Posner said. The new compounds have a similar oxygen-oxygen bond, thereby enabling the same sort of iron-induced reaction.

Malaria is a menace in regions stretching from Africa to the Caribbean islands, and from Central America to Asia and India. The parasite began showing a resistance to chloroquine more than three decades ago, and its resistance is spreading progressively throughout the world.

The disease is spread by a genus of mosquitos called Anopheles, which pick up the parasite when they bite an infected person. The insects then transmit infected blood to other people. Anopheles mosquitos are found in portions of the United States, where reports of malaria have historically been rare but where public health officials are increasingly concerned.

The research was funded by a three-year grant, totaling $740,969, from the National Institutes of Health. That grant was recently renewed by NIH for another four years. Also involved in the work are Xueliang Tao, a postdoctoral fellow in chemistry; Jared N. Cumming, a chemistry graduate student; and Donna Klinedinst, a research assistant in the Johns Hopkins School of Medicine.

Johns Hopkins University

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to